Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Plasma neurotransmitter and circulating exosomal microRNA landmarks during heroin and methamphetamine withdrawal

PROVIDER: PRJNA667326 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR12771400.fastq.gz	Fastqsanger.gz
	SRR12771401.fastq.gz	Fastqsanger.gz
	SRR12771402.fastq.gz	Fastqsanger.gz
	SRR12771403.fastq.gz	Fastqsanger.gz
	SRR12771404.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 69

Similar Datasets

Transcriptional effects of chronic heroin and methamphetamine treatment in the mouse striatum

Project description:To identify molecular effects of chronic drug treatment, heroin and methamphetamine treated animals were compared with saline treated animals at multiple time-points using microarray technology. Gene expression profile was assessed 14 h after the last dose of 1, 3, 6 or 12 days drug treatment and after 13, 15, 18 or 24 days of withdrawal. Animals were injected intraperitoneally with saline (SAL) (Polfa, Lublin, Poland), heroin (synthesized from morphine in Institute of Pharmacology PAS, Krakow, Poland) or D-methamphetamine (Sigma-Aldrich, Poznan, Poland) twice a day for consecutive 12 days in increasing doses. The Methamphetamine last dose (8 mg/kg) was four times greater than the first dose (2 mg/kg). It was also the case for heroin (40 and 10 mg/kg respectively). Mice were sacrificed by decapitation after 1, 3, 6 or 12 days of treatment or after 13, 15, 18 or 24 days of withdrawal.

2012-06-20 | E-GEOD-30305 | biostudies-arrayexpress

Transcriptional effects of chronic heroin and methamphetamine treatment in the mouse striatum

2012-06-21 | GSE30305 | GEO

Integration of molecular inflammatory interactome analyses reveal dynamics of circulating cytokines and extracellular vesicle long non-coding RNAs and mRNAs in heroin addicts during acute and protracted withdrawal

Project description:Heroin addiction and withdrawal influence multiple physiological functions including immune responses, but the mechanism remains largely elusive. The objective of this study was to investigate the immune system function and molecular inflammatory interactome particularly the cytokines and RNA regulatory network in heroin addicts undergoing withdrawal compared healthy controls.

2021-07-03 | GSE172306 | GEO

A multi-center study: the application value of plasma exosomal non-coding RNA in the early screening and clinical progress of colorectal cancer

Project description:Interventions: Gold Standard:Gastroscopy, colonoscopy, pathological diagnosis;Index test:Plasma exosome extraction: commercial plasma exosome extraction kit (EZB company) extraction. Extraction of plasma exosomal miRNA: Advanced probe method RT-qPCR extraction kit (Thermo Company). Primary outcome(s): exosome microRNA Study Design: Cohort study

| 40619 | ecrin-mdr-crc

Determine the differential miRNA levels in plasma of heroin addicts

Project description:To determine the differential miRNA levels in heroin addicts, we comparatively profiled plasma miRNA expression of heroin abusers and healthy controls using Agilent Human miRNA Array.

2020-10-29 | GSE160275 | GEO

Serum is preferable to plasma for circulating exosomal microRNA biomarker discovery studies

Project description:Serum is preferable to plasma for circulating exosomal microRNA biomarker discovery studies

| PRJNA598665 | ENA

Keratinocyte-derived circulating exosomal miRNAs as a novel biomarker of disease severity in psoriasis

Project description:To reveal the relationship between circulating exosomal miRNAs and the disease severity of psoriasis, we performed next-generation sequencing from plasma exosomes of patients with high psoriasis area and severity index (PASI) score (>10) and low PASI score (<5). We identified 19 differentially expressed exosomal miRNAs that were significantly different between the groups. We validated the top three up-and down-regulated exosomal miRNAs using quantitative real-time PCR.

2024-03-13 | GSE215124 | GEO

Histone H3 dopaminylation in ventral tegmental area underlies heroin-induced maladaptive plasticity

Project description:Persistent transcriptional events in ventral tegmental area (VTA) and other reward relevant brain regions contribute to enduring behavioral adaptations that characterize substance use disorder (SUD). Recent data from our laboratory indicate that aberrant accumulation of the newly discovered histone post-translational modification (PTM), H3 dopaminylation at glutamine 5 (H3Q5dop), contributes significantly to cocaine-seeking behavior following prolonged periods of abstinence. It remained unclear, however, whether this modification is important for relapse vulnerability in the context of other drugs of abuse, such as opioids. Here, we showed that H3Q5dop plays a critical role in heroin-mediated transcriptional plasticity in midbrain. In rats undergoing abstinence from heroin self-administration (SA), we found acute and persistent accumulation of H3Q5dop in VTA. By attenuating H3Q5dop during abstinence, we both altered gene expression programs associated with heroin withdrawal and reduced heroin-primed reinstatement behavior. These findings thus establish an essential role for H3Q5dop, and its downstream transcriptional consequences, in opioid-induced plasticity in VTA.

2022-02-20 | GSE169628 | GEO

Determine the differential miRNA levels in plasma exosomes of methamphetamine addicts [miRNA-seq]

Project description:To determine the differential miRNA levels in methamphetamine addicts, we comparatively profiled plasma exosome miRNA expression of methamphetamine abusers and healthy controls using miRNA sequencing

2023-04-20 | GSE224657 | GEO

Determine the differential miRNA levels in plasma of methamphetamine addicts [array]

Project description:To determine the differential miRNA levels in methamphetamine addicts, we comparatively profiled plasma miRNA expression of methamphetamine abusers and healthy controls using Agilent Human miRNA Array.

2023-04-20 | GSE224658 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data